REFERENCES

Publication Details

1.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. [PMC free article: PMC4340604] [PubMed: 25530442]
2.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55. [PubMed: 26231459]
3.
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–S57. [PubMed: 25086286]
4.
Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34 Suppl 1:69–78. [PMC free article: PMC7737539] [PubMed: 24373081]
5.
Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. Geneva: World Health Organization; 2016 (http://apps​.who.int/iris​/bitstream/10665​/205035/1/9789241549615_eng.pdf?ua=1, accessed 6 February 2017). [PubMed: 27227200]
6.
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 (http://apps​.who.int/iris​/bitstream/10665​/154590/1/9789241549059_eng​.pdf?ua=1&ua=1, 6 February 2017). [PubMed: 26225396]
7.
Mathurin P. HCV burden in Europe and the possible impact of current treatment. Dig Liver Dis. 2013;45(Suppl 5):S314–S317. [PubMed: 24091109]
8.
Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51(3):729–33. [PubMed: 20186842]
9.
Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat. 2015;22(4):409–15. [PubMed: 25209157]
10.
Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011;18 (Suppl 1):1–16. [PubMed: 21824223]
11.
Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2015 (http://apps​.who.int/iris​/bitstream/10665​/179870/1/9789241508926_eng​.pdf?ua=1&ua=1, 6 February 2017). [PubMed: 26378328]
12.
Technical considerations and case definitions to improve surveillance for viral hepatitis. Geneva: World Health Organization; 2016 (http://www​.who.int/hepatitis​/publications​/hep-surveillance-guide-pub/en/, accessed 6 February 2017).
13.
Resolution WHA63.18. Viral hepatitis. In: Sixty-third World Health Assembly. Geneva: World Health Organization; 2010 (http://apps​.who.int/gb​/ebwha/pdf_files/WHA63-REC1​/WHA63_REC1-en.pdf accessed 6 February 2017).
14.
Resolution WHA67.6. Hepatitis. In: Sixty-seventh World Health Assembly. Geneva: World Health Organization; 2014 (http://apps​.who.int/gb​/ebwha/pdf_files/WHA67/A67_R6-en.pdf accessed 6 February 2017).
15.
Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014 (http://apps​.who.int/iris​/bitstream/10665​/111747/1/9789241548755_eng​.pdf?ua=1&ua=1, accessed 6 February 2017). [PubMed: 25535634]
16.
WHO global health sector strategy on viral hepatitis. Geneva: World Health Organization; 2016 (http://www​.who.int/hepatitis​/strategy2016-2021​/Draft_global_health​_sector_strategy​_viral_hepatitis_13nov.pdf?ua=1, accessed 16 February 2017).
17.
Hepatitis A. Fact sheet. Geneva: World Health Organization; July 2016 (http://www​.who.int/mediacentre​/factsheets/fs328/en/, accessed 05 February 2017).
18.
Waterborne outbreaks of hepatitis E: recognition, investigation and control. Geneva: World Health Organization; 2014 (http://apps​.who.int/iris​/bitstream/10665​/129448/1/9789241507608_eng​.pdf?ua=1&ua=1, accessed 6 February 2017).
19.
Hepatitis delta. Fact sheet. Geneva: World Health Organization; July 2016 (http://www​.who.int/mediacentre​/factsheets/hepatitis-d/en/, 05 February 2017).
20.
Screening donated blood for transfusion transmissible infections. Geneva: World Health Organization; 2010 (http://www​.who.int/bloodsafety​/ScreeningDonatedBloodforTransfusion.pdf, accessed 6 February 2017). [PubMed: 23741773]
21.
HIV self-testing and partner notification. Geneva: World Health Organization; 2016 (http://apps​.who.int/iris​/bitstream/10665​/251655/1/9789241549868-eng.pdf?ua=1, accessed 19 January 2017). [PubMed: 27977094]
22.
Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework: technical report. Geneva: World Health Organization; 2016 (http://apps​.who.int/iris​/bitstream/10665​/204790/1/9789241510288_eng.pdf, accessed 6 February 2017).
23.
Consolidated guidelines on the use of antiretrovirals for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization; 2016 (http://apps​.who.int/iris​/bitstream/10665​/208825/1/9789241549684_eng.pdf?ua=1, accessed 6 February 2017). [PubMed: 27466667]
24.
Hepatitis B vaccines. Wkly Epidemiol Rec. 2009;84:405–20. [PubMed: 19817017]
25.
Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014 (http://apps​.who.int/iris​/bitstream/10665​/128048/1/9789241507431_eng​.pdf?ua=1&ua=1, accessed 6 February 2017). [PubMed: 25996019]
26.
Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people. Geneva: World Health Organization; 2011 (http://apps​.who.int/iris​/bitstream/10665​/44619/1/9789241501750_eng.pdf, accessed 6 February 2017). [PubMed: 26158187]
27.
Prevention and treatment of HIV and other sexually transmitted infections for sex workers in low- and middle-income countries: recommendations for a public health approach. Geneva: World Health Organization; 2012 (https://www​.unfpa.org​/sites/default/files​/pub-pdf/9789241504744_eng.pdf, accessed 6 February 2017). [PubMed: 26131541]
28.
Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization; 2012 (http://apps​.who.int/iris​/bitstream/10665​/75357/1/9789241504041_eng.pdf?ua=1, accessed 18 December 2016). [PubMed: 23805439]
29.
WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009 (http://apps​.who.int/iris​/bitstream/10665​/44102/1/9789241597906_eng.pdf, accessed 6 February 2017).
30.
Universal access to safe blood transfusion. Geneva: World Health Organization; 2008 (http://www​.who.int/bloodsafety​/publications​/UniversalAccesstoSafeBT.pdf?ua=1, accessed 6 February 2017).
31.
WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings. Geneva: World Health Organization; 2016. [PubMed: 27748094]
32.
The Universal Declaration of Human Rights. Geneva: United Nations; 1948 (http://www​.un.org/en​/documents/udhr/index.shtml, accessed 6 February 2017).
33.
Handbook for guideline development, second edition. Geneva: World Health Organization; 2014 (http://apps​.who.int/iris​/bitstream/10665​/145714/1/9789241548960_eng.pdf, accessed 6 February 2017).
34.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. [PubMed: 21195583]
35.
Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6. [PubMed: 21208779]
36.
Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400. [PubMed: 21194891]
37.
Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719–25. [PubMed: 23312392]
38.
Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106–10. [PMC free article: PMC2386626] [PubMed: 18483053]
39.
Gopalakrishna G, Mustafa RA, Davenport C, Scholten RJ, Hyde C, Brozek J et al. Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable. J Clin Epidemiol. 2014;67(7):760–8. [PubMed: 24725643]
40.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. [PubMed: 22007046]
41.
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407–15. [PubMed: 21247734]
42.
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J et al. GRADE guidelines: 5. Rating the quality of evidence – publication bias. J Clin Epidemiol. 2011;64(12):1277–82. [PubMed: 21802904]
43.
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D et al. GRADE guidelines 6. Rating the quality of evidence – imprecision. J Clin Epidemiol. 2011;64(12):1283–93. [PubMed: 21839614]
44.
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M et al. GRADE guidelines: 7. Rating the quality of evidence – inconsistency. J Clin Epidemiol. 2011;64(12):1294–302. [PubMed: 21803546]
45.
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M et al. GRADE guidelines: 8. Rating the quality of evidence – indirectness. J Clin Epidemiol. 2011;64(12):1303–10. [PubMed: 21802903]
46.
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83. [PMC free article: PMC3285467] [PubMed: 21802134]
47.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–39. [PubMed: 17256718]
48.
Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depen. 2007;89(1):1–12. [PMC free article: PMC1892753] [PubMed: 17174481]
49.
El Maerrawi I, Carvalho HB. Prevalence and risk factors associated with HIV infection, hepatitis and syphilis in a state prison of Sao Paulo. Int J STD AIDS. 2015;26(2):120–7. [PubMed: 24733152]
50.
Evidence for action technical papers: effectiveness of interventions to address HIV in prisons. Geneva: World Health Organization; 2007 (http://apps​.who.int/iris​/bitstream/10665​/43806/1/9789241596190_eng.pdf, accessed 6 February 2017).
51.
Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215–24. [PMC free article: PMC3723697] [PubMed: 23504650]
52.
Padovese V, Egidi AM, Melillo TF, Farrugia B, Carabot P, Didero D et al. Prevalence of latent tuberculosis, syphilis, hepatitis B and C among asylum seekers in Malta. J Public Health (Oxf). 2014;36(1):22–7. [PubMed: 23559596]
53.
Policy statement on HIV testing and counselling for refugees and other persons of concern to UNHCR. Geneva: United Nations High Commissioner for Refugees; 2014 (http://www​.unhcr.org/53a816729.pdf, accessed 6 February 2017).
54.
Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. [PMC free article: PMC3716892] [PubMed: 23597411]
55.
Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people: annual surveillance report 2015. Sydney, Australia: The Kirby Institute for infection and immunity in society 2015 (https://kirby​.unsw.edu​.au/sites/default/files​/hiv/resources/atsip2015_v3.pdf, accessed 8 February 2017).
56.
Implementing comprehensive HIV/STI programmes with sex workers: practical approaches from collaborative interventions. Geneva: World Health Organization; 2013 (http://apps​.who.int/iris​/bitstream/10665​/90000/1/9789241506182_eng.pdf, accessed 6 February 2017).
57.
Policy brief: transgender people and HIV. Geneva: World Helath Organization; 2015 (http://apps​.who.int/iris​/bitstream/10665​/179517/1/WHO_HIV_2015.17_eng.pdf?ua=1, accessed 5 February 2017).
58.
Diamond C, Thiede H, Perdue T, Secura GM, Valleroy L, Mackellar D et al. Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. Sex Transm Dis. 2003;30(5):425–32. [PubMed: 12916134]
59.
Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52(4):1497–505. [PubMed: 20635398]
60.
Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88(7):558–64. [PubMed: 22859499]
61.
Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis.2013;26(1):66–72. [PubMed: 23242342]
62.
Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: The Swiss HIV cohort study. Clin Infect Dis. 2005;41(3):395–402. [PubMed: 16007539]
63.
van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009;136(5):1609–17. [PMC free article: PMC4260925] [PubMed: 19422083]
64.
Fierer DS, Uriel AJ, Carriero DC, Klepper A, Dieterich DT, Mullen MP et al. Liver fibrosis during an outbreak of acute hepatitis c virus infection in HIV-infected men: a prospective cohort study. J Infect Dis. 2008;198(5):683–6. [PMC free article: PMC4520699] [PubMed: 18627270]
65.
Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983–91. [PubMed: 17457092]
66.
Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, Bouvet E, Yazdanpanah Y. Blood-borne viruses in health care workers: prevention and management. J Clin Virol. 2011;52(1):4–10. [PubMed: 21680238]
67.
Lee R. Occupational transmission of bloodborne diseases to healthcare workers in developing countries: meeting the challenges. J Hosp Infect. 2009;72(4):285–91. [PubMed: 19443081]
68.
Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev. 2000;13(3):385–407. [PMC free article: PMC88939] [PubMed: 10885983]
69.
Global database on blood safety. In: Blood transfusion safety [webpage]. Geneva: World Health Organization; 2011 (http://www​.who.int/bloodsafety​/global_database/en/, accessed 6 February 2017).
70.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Inf Dis. 2005;5(9):558–67. [PubMed: 16122679]
71.
Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91. [PubMed: 10752705]
72.
Singh S, Dwivedi SN, Sood R, Wali JP. Hepatitis B, C and human immunodeficiency virus infections in multiply-injected kala-azar patients in Delhi. Scand J Infect Dis. 2000;32(1):3–6. [PubMed: 10716069]
73.
Marx MA, Murugavel KG, Sivaram S, Balakrishnan P, Steinhoff M, Anand S et al. The association of health-care use and hepatitis C virus infection in a random sample of urban slum community residents in southern India. Am J Trop Med Hyg. 2003;68(2):258–62. [PubMed: 12641422]
74.
Wang CS, Chang TT, Chou P. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J Clin Epidemiol. 1998;51(9):733–8. [PubMed: 9731921]
75.
Ho MS, Hsu CP, Yuh Y, King CC, Tsai JF. High rate of hepatitis C virus infection in an isolated community: persistent hyperendemicity or period-related phenomena? J Med Virol. 1997;52(4):370–6. [PubMed: 9260682]
76.
Lin CC, Hwang SJ, Chiou ST, Kuan CL, Chen LW, Lee TC et al. The prevalence and risk factors analysis of serum antibody to hepatitis C virus in the elders in northeast Taiwan. J Chin Med Assoc. 2003;66(2):103–8. [PubMed: 12716008]
77.
Saxena R, Thakur V, Sood B, Guptan RC, Gururaja S, Sarin SK. Transfusion-associated hepatitis in a tertiary referral hospital in India. A prospective study. Vox Sang. 1999;77(1):6–10. [PubMed: 10474084]
78.
Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br J Haematol. 2001;113(1):37–9. [PubMed: 11328277]
79.
Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], ICF International. Egypt Demographic and Health Survey 2014. Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International; 2015.
80.
Omar N, Salama K, Adolf S, El-Saeed GS, Abdel Ghaffar N, Ezzat N. Major risk of blood transfusion in hemolytic anemia patients. Blood Coagul Fibrinolysis. 2011;22(4):280–4. [PubMed: 21508832]
81.
Ghosh K, Joshi SH, Shetty S, Pawar A, Chipkar S, Pujari V et al. Transfusion transmitted diseases in haemophilics from western India. Indian J Med Res. 2000;112:61–4. [PubMed: 11037680]
82.
Arababadi MK, Nasiri Ahmadabadi B, Yousefi Daredor H, Kennedy D. Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients. Hepat Mon. 2012;12(5):315–9. [PMC free article: PMC3389356] [PubMed: 22783342]
83.
Nishioka Sde A, Gyorkos TW, Joseph L, Collet JP, Maclean JD. Tattooing and risk for transfusion-transmitted diseases: the role of the type, number and design of the tattoos, and the conditions in which they were performed. Epidemiol Infect. 2002;128(1):63–71. [PMC free article: PMC2869796] [PubMed: 11895092]
84.
Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010;14(11):E928–E940. [PubMed: 20678951]
85.
Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G. A case control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat. 2006;13(11):775–82. [PubMed: 17052278]
86.
Ezechi OC, Kalejaiye OO, Gab-Okafor CV, Oladele DA, Oke BO, Musa ZA et al. Sero-prevalence and factors associated with hepatitis B and C co-infection in pregnant Nigerian women living with HIV infection. Pan Afr Med J. 2014;17:197. [PMC free article: PMC4229000] [PubMed: 25396023]
87.
Easterbrook PJ, Platt L, Gower E, McDonald B, Sabin K, McGowan C et al. Global systematic review and meta-analysis of the seroprevalence of HBV and HCV infection in HIV-infected persons. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2015. [Abstract No TU PEB254].
88.
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808. [PubMed: 26922272]
89.
Karuru JW, Lule GN, Joshi M, Anzala O. Prevalence of HCV and HCV/HIV co-infection among in-patients at the Kenyatta National Hospital. East Afr Med J. 2005;82(4):170–2. [PubMed: 16122083]
90.
Quaranta JF, Delaney SR, Alleman S, Cassuto JP, Dellamonica P, Allain JP. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J Med Virol. 1994;42(1):29–32. [PubMed: 7508489]
91.
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7. [PubMed: 11833007]
92.
D'Oliveira A, Jr., Voirin N, Allard R, Peyramond D, Chidiac C, Touraine JL et al. Prevalence and sexual risk of hepatitis C virus infection when human immunodeficiency virus was acquired through sexual intercourse among patients of the Lyon University Hospitals, France, 1992–2002. J Viral Hepat. 2005;12(3):330–2. [PubMed: 15850476]
93.
Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55 (Suppl 1):S33–S42. [PMC free article: PMC3491862] [PubMed: 22715212]
94.
Shimakawa Y, Toure-Kane C, Mendy M, Thursz M, Lemoine M. Mother-to-child transmission of hepatitis B in sub-Saharan Africa. Lancet Infect Dis. 2016;16(1):19–20. [PubMed: 26738828]
95.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 2004;24 (Suppl 1):17–21. [PubMed: 15192797]
96.
Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis. 1998;177(6):1480–8. [PubMed: 9607823]
97.
Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765–73. [PMC free article: PMC4144266] [PubMed: 24928290]
98.
Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880–9. [PubMed: 16267758]
99.
Floreani A. Hepatitis C and pregnancy. World J Gastroenterol. 2013;19(40):6714–20. [PMC free article: PMC3812470] [PubMed: 24187446]
100.
Camarero C, Martos I, Delgado R, Suarez L, Escobar H, Mateos M. Horizontal transmission of hepatitis C virus in households of infected children. J Pediatr. 1993;123(1):98–9. [PubMed: 8391573]
101.
Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;11(1):28–35. [PubMed: 24080775]
102.
Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881–9. [PMC free article: PMC4384338] [PubMed: 23175457]
103.
Gupta S, Gupta R, Joshi YK, Singh S. Role of horizontal transmission in hepatitis B virus spread among household contacts in north India. Intervirology. 2008;51(1):7–13. [PubMed: 18309243]
104.
Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol. 2004;99(5):855–9. [PubMed: 15128350]
105.
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38. [PubMed: 16879891]
106.
Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329–39. [PubMed: 16249217]
107.
Yi P, Chen R, Huang Y, Zhou RR, Fan XG. Management of mother-to-child transmission of hepatitis B virus: propositions and challenges. J Clin Virol. 2016;77:32–9. [PubMed: 26895227]
108.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. [PMC free article: PMC4722087] [PubMed: 26563120]
109.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107. [PubMed: 14996343]
110.
Yonghao G, Jin X, Jun L, Pumei D, Ying Y, Xiuhong F et al. An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China. Int J Infect Dis. 2015;40:75–80. [PubMed: 26456567]
111.
Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201. [PubMed: 20533878]
112.
Head-to-head comparison of two years efficacy of entecavir and tenofovir in patients with treatment naive chronic hepatitis B – the real life data. Hepatogastroenterology. 2015;62(140):982–6. [PubMed: 26902041]
113.
Hadziyannis SJ. Update on hepatitis B virus infection: focus on treatment. J Clin Transl Hepatol. 2014;2(4):285–91. [PMC free article: PMC4521240] [PubMed: 26355326]
114.
Rao VB, Johari N, du Cros P, Messina J, Ford N, Cooke GS. Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(7):819–24. [PubMed: 25957078]
115.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128. [PubMed: 23245604]
116.
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21:34–59. [PubMed: 24713005]
117.
Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991;115(10):764–8. [PubMed: 1656825]
118.
Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32(3):492–7. [PubMed: 11170959]
119.
Ministry of Health and Population (Egypt), El-Zanaty and Associates (Egypt), ICF International. Egypt health issues survey 2015. Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International; 2015.
120.
Global database on blood safety. Summary report 2011. Geneva: World Health Organization; 2011 (http://www​.who.int/bloodsafety​/global_database​/GDBS_Summary_Report_2011.pdf?ua=1, accessed 6 February 2017).
121.
Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect. 2003;79(2):160–2. [PMC free article: PMC1744643] [PubMed: 12690143]
122.
Tseng YT, Sun HY, Chang SY, Wu CH, Liu WC, Wu PY et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18–40 years in Taiwan. J Formos Med Assoc. 2012;111(8):431–8. [PubMed: 22939661]
123.
Price H, Gilson R, Mercey D, Copas A, Parry J, Nardone A et al. Hepatitis C in men who have sex with men in London – a community survey. HIV Med. 2013;14(9):578–80. [PMC free article: PMC4016752] [PubMed: 23782450]
124.
Metwally A, Mohsen A, Saleh R, Foaud W, Ibrahim N, Rabaah T et al. Prioritizing high-risk practices and exploring new emerging ones associated with hepatitis C virus infection in Egypt. Iranian J Publ Health. 2014;43(10):1385–94. [PMC free article: PMC4441892] [PubMed: 26060701]
125.
Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156(4):263–70. [PMC free article: PMC5484577] [PubMed: 22056542]
126.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. [PubMed: 23172780]
127.
Alonso M, Gutzman A, Mazin R, Pinzon CE, Reveiz L, Ghidinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health. 2015;60(7):789–98. [PMC free article: PMC4636523] [PubMed: 26298439]
128.
Chen Y, Shen Z, Morano JP, Khoshnood K, Wu Z, Lan G et al. Bridging the epidemic: a comprehensive analysis of prevalence and correlates of HIV, hepatitis C, and syphilis, and infection among female sex workers in Guangxi Province, China. PLoS One. 2015;10(2):e0115311. [PMC free article: PMC4344209] [PubMed: 25723548]
129.
Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS. 2015;29(17):2335–45. [PMC free article: PMC4640945] [PubMed: 26258525]
130.
Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–20. [PMC free article: PMC3972017] [PubMed: 23908124]
131.
Tong MJ, Elfarra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis-C. N Engl J Med. 1995;332(22):1463–6. [PubMed: 7739682]
132.
Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992;16(3):273–81. [PubMed: 1487603]
133.
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–31. [PubMed: 18563841]
134.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. [PubMed: 17570226]
135.
Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol. 2001;8(3):200–6. [PubMed: 11499958]
136.
Abdelrahim SS, Khiry RM, Esmail MA, Ragab M, Abdel-Hamid M, Abdelwahab SF. Occult hepatitis C virus infection among Egyptian hemodialysis patients. J Med Virol. 2016;88(8):1388–93. [PubMed: 26743014]
137.
El-Shishtawy S, Sherif N, Abdallh E, Kamel L, Shemis M, Saleem AA et al. Occult hepatitis C virus infection in hemodialysis patients; single center study. Electron Physician. 2015;7(8):1619–25. [PMC free article: PMC4725416] [PubMed: 26816589]
138.
Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F et al. Occult HCV infection: the current state of knowledge. Iran Red Crescent Med J. 2015;17(11):e34181. [PMC free article: PMC4698335] [PubMed: 26734487]
139.
Blood donor selection: guidelines on assessing donor suitability for blood donation. Geneva: World Health Organization; 2012 (http://www​.ncbi.nlm.nih​.gov/pubmed/23700651, accessed 6 February 2017). [PubMed: 23700651]
140.
WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: World Health Organization; 2012 revision (http://apps​.who.int/iris​/bitstream/10665​/77969/1/9789241504379_eng.pdf?ua=1, accessed 6 February 2017).
141.
Allain JP, Opare-Sem O, Sarkodie F, Rahman R, Owusu-Ofori S. Deferred donor care in a regional hospital blood center in Ghana. Transfusion. 2009;49(4):669–75. [PubMed: 19170991]
142.
Pollack H, Wang S, Wyatt L, Peng CH, Wan K, Trinh-Shevrin C et al. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff (Millwood). 2011;30(10):1974–83. [PMC free article: PMC3333793] [PubMed: 21976342]
143.
Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 2011;52(11):1294–306. [PMC free article: PMC3097367] [PubMed: 21540206]
144.
Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568–78. [PubMed: 27443782]
145.
Wong WW, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int. 2011;31(8):1179–90. [PubMed: 21745300]
146.
Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One. 2013;8(10):e78548. [PMC free article: PMC3799697] [PubMed: 24205255]
147.
Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007;147(7):460–9. [PubMed: 17909207]
148.
Veldhuijzen IK, Toy M, Hahne SJ, De Wit GA, Schalm SW, de Man RA et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology. 2010;138(2):522–30. [PubMed: 19879275]
149.
Rein DB, Lesesne SB, Smith BD, Weinbaum CM. Models of community-based hepatitis B surface antigen screening programs in the US and their estimated outcomes and costs. Public Health Rep. 2011;126(4):560–7. [PMC free article: PMC3115215] [PubMed: 21800750]
150.
Jazwa A, Coleman MS, Gazmararian J, Wingate LT, Maskery B, Mitchell T et al. Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential? Vaccine. 2015;33(11):1393–9. [PMC free article: PMC4633992] [PubMed: 25595868]
151.
Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy. 2011;102(1):72–80. [PubMed: 21035229]
152.
Lemoine M, Shimakawa Y, Nije R, Taal M, Ndow G, Chemin I et al., on behalf of the PROLIFICA investigators. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016;4(8):e559–e567. [PubMed: 27443781]
153.
Easterbrook P, Johnson C, Figueroa C, Baggaley R. HIV and hepatitis testing: global progress, challenges and future directions. AIDS Rev. 2016;18:3–14. [PubMed: 26991825]
154.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9. [PubMed: 22273662]
155.
Qvist T, Cowan SA, Graugaard C, Helleberg M. High linkage to care in a community-based rapid HIV testing and counseling project among men who have sex with men in Copenhagen. Sex Transm Dis. 2014;41(3):209–14. [PubMed: 24521728]
156.
Hensen B, Baggaley R, Wong VJ, Grabbe KL, Shaffer N, Lo YR et al. Universal voluntary HIV testing in antenatal care settings: a review of the contribution of provider-initiated testing & counselling. Trop Med Int Health. 2012;17(1):59–70. [PubMed: 22032300]
157.
Thio CL, Guo N, Xie C, Nelson KE, Ehrhardt S. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect Dis. 2015;15(8):981–5. [PubMed: 26145195]
158.
Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin NK et al. Cost-effectiveness of HBV and HCV screening strategies – a systematic review of existing modelling techniques. PLoS One. 2015;10(12):e0145022. [PMC free article: PMC4686364] [PubMed: 26689908]
159.
Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess.2006;10(32):iii–iv, ix–xii, 1–93. [PubMed: 16948891]
160.
Loubiere S, Rotily M, Moatti JP. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care. 2003;19(4):632–45. [PubMed: 15095769]
161.
Loubiere S, Rotily M, Moatti JP. [Medico-economic assessment of the therapeutic management of patients with hepatitis C]. Gastroenterol Clin Biol. 2000;24(11):1047–51. [PubMed: 11139674]
162.
Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med. 2008;215(1):33–42. [PubMed: 18509233]
163.
Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med. 2001;111(8):614–21. [PubMed: 11755504]
164.
Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. J Hepatol. 2003;39(5):814–25. [PubMed: 14568266]
165.
Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54(9):1259–71. [PMC free article: PMC3404694] [PubMed: 22412061]
166.
McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55(5):1344–55. [PubMed: 22135116]
167.
Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis. 2013;56(10):1382–93. [PubMed: 23392392]
168.
Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One. 2013;8(3):e58975. [PMC free article: PMC3606430] [PubMed: 23533595]
169.
Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol. 1998;93(4):591–6. [PubMed: 9576453]
170.
Wong WW, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015;187(3):E110–21. [PMC free article: PMC4330166] [PubMed: 25583667]
171.
Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A. Economic assessment of an anti-HCV screening program in Italy. Value Health. 2013;16(6):965–72. [PubMed: 24041346]
172.
Honeycutt AA, Harris JL, Khavjou O, Buffington J, Jones TS, Rein DB. The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep. 2007;122 (Suppl 2):55–62. [PMC free article: PMC1831797] [PubMed: 17542455]
173.
Josset V, Torre JP, Tavolacci MP, Van Rossem-Magnani V, Anselme K, Merle V et al. Efficiency of hepatitis C virus screening strategies in general practice. Gastroenterol Clin Biol. 2004;28(4):351–7. [PubMed: 15146150]
174.
Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? J Med Screen. 1999;6(3):124–31. [PubMed: 10572842]
175.
Stein K, Dalziel K, Walker A, Jenkins B, Round A, Royle P. Screening for hepatitis C in injecting drug users: a cost utility analysis. J Public Health (Oxf). 2004;26(1):61–71. [PubMed: 15044577]
176.
Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health. 2006;6:170. [PMC free article: PMC1543636] [PubMed: 16803622]
177.
Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008;15(11):797–808. [PubMed: 18637074]
178.
Thompson Coon J, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract. 2006;23(4):393–406. [PubMed: 16799165]
179.
Tramarin A, Gennaro N, Compostella FA, Gallo C, Wendelaar Bonga LJ, Postma MJ. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des. 2008;14(17):1655–60. [PubMed: 18673188]
180.
Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR et al. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2015;110(1):129–43. [PMC free article: PMC4270906] [PubMed: 25291977]
181.
Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One. 2012;7(9):e45176. [PMC free article: PMC3445468] [PubMed: 23028828]
182.
Jusot JF, Colin C. Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients. Eur J Public Health. 2001;11(4):373–9. [PubMed: 11766476]
183.
Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis. 2012;55(2):279–90. [PMC free article: PMC3403839] [PubMed: 22491339]
184.
Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol. 2005;192(4):1153–61. [PubMed: 15846195]
185.
Urbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A et al. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS One. 2013;8(8):e70319. [PMC free article: PMC3741285] [PubMed: 23950920]
186.
Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Gut. 2009;58(1):105–10. [PMC free article: PMC2597690] [PubMed: 18824553]
187.
Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014;21(9):616–23. [PubMed: 24215210]
188.
Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3(8). [PMC free article: PMC3752052] [PubMed: 23943776]
189.
Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137–44. [PubMed: 21145810]
190.
Brogueira P, Costa A, Miranda A, Peres S, Baptista T, Aldir I et al. Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19601. [PMC free article: PMC4224779] [PubMed: 25394105]
191.
Kim DD, Hutton DW, Raouf AA, Salama M, Hablas A, Seifeldin IA et al. Cost-effectiveness model for hepatitis C screening and treatment: implications for Egypt and other countries with high prevalence. Glob Public Health. 2015;10(3):296–317. [PMC free article: PMC4320005] [PubMed: 25469976]
192.
Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep. 2014;16(4):381. [PubMed: 24595618]
193.
Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis M. A systematic review of the effectiveness and cost-effectiveness of interventions aimed at raising awareness and engaging with groups who are at an increased risk of hepatitis B and C infection – final report. Liverpool: Centre for Public Health, Faculty of Health and Applied Social Sciences, Liverpool John Moores University; 2012.
194.
Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10(8):e1001496. [PMC free article: PMC3742447] [PubMed: 23966838]
195.
Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81(4):719–34. [PMC free article: PMC3455918] [PubMed: 15466851]
196.
Gunn RA, Lee MA, Callahan DB, Gonzales P, Murray PJ, Margolis HS. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. Am J Prev Med. 2005;29(1):27–33. [PubMed: 15958248]
197.
Mvere D, Constantine NT, Katsawde E, Tobaiwa O, Dambire S, Corcoran P. Rapid and simple hepatitis assays: encouraging results from a blood donor population in Zimbabwe. Bull World Health Organ. 1996;74(1):19–24. [PMC free article: PMC2486854] [PubMed: 8653812]
198.
Sato K, Ichiyama S, Iinuma Y, Nada T, Shimokata K, Nakashima N. Evaluation of immunochromatographic assay systems for rapid detection of hepatitis B surface antigen and antibody, Dainascreen HBsAg and Dainascreen Ausab. J Clin Microbiol. 1996;34(6):1420–2. [PMC free article: PMC229035] [PubMed: 8735091]
199.
Abraham P, Sujatha R, Raghuraman S, Subramaniam T, Sridharan G. Evaluation of two immunochromatographic assays in relation to ‘RAPID’ screening of HBsAG. Indian J Med Microbiol. 1998;16(1):23–5.
200.
Oh J, Kim T, Yoon H, Min H, Lee H, Choi T. Evaluation of Genedia® HBsAg rapid and Genedia® anti- HBs rapid for the screening of HBsAg and anti-HBs. Korean J Clin Pathol. 1999;19(1):114–7.
201.
Kaur H, Dhanao J, Oberoi A. Evaluation of rapid kits for detection of HIV, HBsAg and HCV infections. Indian J Med Sci. 2000;54(10):432–4. [PubMed: 11262859]
202.
Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R et al. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 2000;62(2):301–9. [PubMed: 10813489]
203.
Raj AA, Subramaniam T, Raghuraman S, Abraham P. Evaluation of an indigenously manufactured rapid immunochromatographic test for detection of HBsAg. Indian J Pathol Microbiol. 2001;44(4):413–4. [PubMed: 12035352]
204.
Clement F, Dewint P, Leroux-Roels G. Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen. J Clin Microbiol. 2002;40(12):4603–6. [PMC free article: PMC154615] [PubMed: 12454159]
205.
Lau DT, Ma H, Lemon SM, Doo E, Ghany MG, Miskovsky E et al. A rapid immunochromatographic assay for hepatitis B virus screening. J Viral Hepat. 2003;10(4):331–4. [PubMed: 12823602]
206.
Akanmu AS, Esan OA, Adewuyi JO, Davies AO, Okany CC, Olatunji RO et al. Evaluation of a rapid test kit for detection of HBsAg/eAg in whole blood: a possible method for pre-donation testing. Afr J Med Med Sci. 2006;35(1):5–8. [PubMed: 17209320]
207.
Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect. 2008;57(1):72–7. [PubMed: 18555534]
208.
Lin YH, Wang Y, Loua A, Day GJ, Qiu Y, Nadala ECJ et al. Evaluation of a new hepatitis B virus surface antigen rapid test with improved sensitivity. J Clin Microbiol. 2008;46(10):3319–24. [PMC free article: PMC2566085] [PubMed: 18701669]
209.
Randrianirina F, Carod JF, Ratsima E, Chretien JB, Richard V, Talarmin A. Evaluation of the performance of four rapid tests for detection of hepatitis B surface antigen in Antananarivo, Madagascar. J Virol Methods. 2008;151(2):294–7. [PubMed: 18462816]
210.
Ola SO, Otegbayo JA, Yakubu A, Aje AO, Odaibo GN, Shokunbi W. Pitfalls in diagnosis of hepatitis B virus infection among adult Nigerians. Niger J Clin Pract. 2009;12(4):350–4. [PubMed: 20329669]
211.
Khan J, Lone D, Hameed A, Munim R, Bhatti M, Khattak A et al. Evaluation of the performance of two rapid immunochromatographic tests for detection of hepatitis B surface antigen and anti HCV antibodies using ELISA tested samples. Ann King Edw Med Univ. 2010;16(1):84–7.
212.
Davies J, van Oosterhout JJ, Nyirenda M, Bowden J, Moore E, Hart IJ et al. Reliability of rapid testing for hepatitis B in a region of high HIV endemicity. Trans R Soc Trop Med Hyg. 2010;104(2):162–4. [PubMed: 19931107]
213.
Bjoerkvoll B, Viet L, Ol HS, Lan NT, Sothy S, Hoel H et al. Screening test accuracy among potential blood donors of HBsAg, anti-HBc and anti-HCV to detect hepatitis B and C virus infection in rural Cambodia and Vietnam. Southeast Asian J Trop Med Public Health. 2010;41(5):1127–35. [PubMed: 21073033]
214.
Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M et al. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010;48(9):3223–30. [PMC free article: PMC2937686] [PubMed: 20631103]
215.
Hoffmann CJ, Dayal D, Cheyip M, McIntyre JA, Gray GE, Conway S et al. Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. Int J STD AIDS. 2012;23(10):e10–e3. [PMC free article: PMC3724418] [PubMed: 23104758]
216.
Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A et al. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol. 2013;58(3):473–8. [PubMed: 23183527]
217.
Chameera E, Noordeen F, Pandithasundara H, Abeykoon A. Diagnostic efficacy of rapid assays used for the detection of hepatitis B virus surface antigen. Sri Lankan Journal of Infectious Diseases. 2013;3(2):21–7.
218.
Franzeck FC, Ngwale R, Msongole B, Hamisi M, Abdul O, Henning L et al. Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania. PLoS One. 2013;8(3):e58468. [PMC free article: PMC3585939] [PubMed: 23469281]
219.
Chevaliez S, Challine D, Naija H, Luu TC, Laperche S, Nadala L et al. Performance of a new rapid test for the detection of hepatitis B surface antigen in various patient populations. J Clin Virol. 2014;59(2):89–93. [PubMed: 24355522]
220.
Erhabor O, Kwaifa I, Bayawa A, Isaac Z, Dorcas I, Sani I. Comparison of ELISA and rapid screening techniques for the detection of HBsAg among blood donors in Usmanu Danfodiyo University Teaching Hospital Sokoto, North Western Nigeria. J Blood Lymph. 2013;4(2):124.
221.
Gish RG, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B et al. A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation. J Viral Hepat. 2014;21(12):905–8. [PMC free article: PMC4263238] [PubMed: 24779356]
222.
Honge B, Jespersen S, Medina C, Te D, da Silva Z, Ostergaard L et al. Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests underestimate hepatitis prevalence among HIV-infected patients. HIV Med. 2014;15(9):571–6. [PubMed: 24717010]
223.
Liu C, Chen T, Lin J, Chen H, Chen J, Lin S et al. Evaluation of the performance of four methods for detection of hepatitis B surface antigen and their application for testing 116,455 specimens. J Virol Methods. 2014;196:174–8. [PubMed: 24239632]
224.
Mutocheluh M, Owusu M, Kwofie TB, Akadigo T, Appau E, Narkwa PW. Risk factors associated with hepatitis B exposure and the reliability of five rapid kits commonly used for screening blood donors in Ghana. BMC Res Notes. 2014;7:873. [PMC free article: PMC4295511] [PubMed: 25475050]
225.
Upreti SR, Gurung S, Patel M, Dixit SM, Krause LK, Shakya G et al. Prevalence of chronic hepatitis B virus infection before and after implementation of a hepatitis B vaccination program among children in Nepal. Vaccine. 2014;32(34):4304–9. [PMC free article: PMC4663719] [PubMed: 24951865]
226.
Njai HF, Shimakawa Y, Sanneh B, Ferguson L, Ndow G, Mendy M et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J Clin Microbiol. 2015;53(4):1156–63. [PMC free article: PMC4365211] [PubMed: 25631805]
227.
Ol HS, Bjoerkvoll B, Sothy S, Van Heng Y, Hoel H, Husebekk A et al. Prevalence of hepatitis B and hepatitis C virus infections in potential blood donors in rural Cambodia. Southeast Asian J Trop Med Public Health. 2009;40(5):963–71. [PubMed: 19842380]
228.
Peng J, Cheng L, Yin B, Guan Q, Liu Y, Wu S et al. Development of an economic and efficient strategy to detect HBsAg: application of ‘gray-zones’ in ELISA and combined use of several detection assays. Clin Chim Acta. 2011;412(23–24):2046–51. [PubMed: 21266169]
229.
Viet L, Lan NT, Ty PX, Bjorkvoll B, Hoel H, Gutteberg T et al. Prevalence of hepatitis B & hepatitis C virus infections in potential blood donors in rural Vietnam. Indian J Med Res. 2012;136(1):74–81. [PMC free article: PMC3461722] [PubMed: 22885267]
230.
Scheiblauer H, El-Nageh M, Diaz S, Nick S, Zeichhardt H, Grunert HP et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang. 2010;98(3 Pt 2):403–14. [PMC free article: PMC2860763] [PubMed: 20412171]
231.
National HBV testing policy. Sydney: Australasian Society for HIV, Viral hepatitis and Sexual Health Medicine; 2012 (http:​//testingportal​.ashm.org.au/images/HepB​_TESTING_POLICY_MARCH2014_V1​.1_FOR%20PRINT.pdf, accessed 5 February 2017).
232.
Gao F, Talbot EA, Loring CH, Power JJ, Dionne-Odom J, Alroy-Preis S et al. Performance of the OraQuick HCV rapid antibody test for screening exposed patients in a hepatitis C outbreak investigation. J Clin Microbiol. 2014;52(7):2650–2. [PMC free article: PMC4097725] [PubMed: 24789176]
233.
Hess KL, Fisher DG, Reynolds GL. Sensitivity and specificity of point-of-care rapid combination syphilis- HIV-HCV tests. PLoS One. 2014;9(11):e112190. [PMC free article: PMC4223032] [PubMed: 25375138]
234.
Hui AY, Chan FK, Chan PK, Tam JS, Sung JJ. Evaluation of a new rapid whole-blood serological test for hepatitis c virus. Acta Virol. 2002;46(1):47–8. [PubMed: 12197634]
235.
Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011;172(1–2):27–31. [PubMed: 21182871]
236.
Al-Tahish G, El-Barrawy MA, Hashish MH, Heddaya Z. Effectiveness of three types of rapid tests for the detection of hepatitis C virus antibodies among blood donors in Alexandria, Egypt. J Virol Methods. 2013;189(2):370–4. [PubMed: 23541785]
237.
Buti M, Cotrina M, Chan H, Jardi R, Rodriguez F, Costa X et al. Rapid method for the detection of anti- HCV antibodies in patients with chronic hepatitis C. Rev Esp Enferm Dig. 2000;92(3):140–6. [PubMed: 10799944]
238.
Cha YJ, Park Q, Kang ES, Yoo BC, Park KU, Kim JW et al. Performance evaluation of the OraQuick hepatitis C virus rapid antibody test. Ann Lab Med. 2013;33(3):184–9. [PMC free article: PMC3646192] [PubMed: 23667844]
239.
da Rosa L, Dantas-Correa EB, Narciso-Schiavon JL, Schiavon L de L. Diagnostic performance of two point-of-care tests for anti-HCV detection. Hepat Mon. 2013;13(9):e12274. [PMC free article: PMC3830521] [PubMed: 24282422]
240.
Ibrahim S, Al Attas SA, Mansour GA, Ouda S, Fallatah H. Accuracy of rapid oral HCV diagnostic test among a Saudi sample. Clin Oral Investig. 2015;19(2):475–80. [PubMed: 24846644]
241.
Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J Clin Virol. 2012;54(3):213–7. [PMC free article: PMC5484575] [PubMed: 22560051]
242.
Kosack CS, Nick S, Shanks L. Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies. J Virol Methods. 2014;204:6–10. [PubMed: 24726704]
243.
Kim MH, Kang SY, Lee WI. Evaluation of a new rapid test kit to detect hepatitis C virus infection. J Virol Methods. 2013;193(2):379–82. [PubMed: 23871756]
244.
Montebugnoli L, Borea G, Miniero R, Sprovieri G. A rapid test for the visual detection of anti-hepatitis C virus antibodies in whole blood. Clin Chim Acta. 1999;288(1–2):91–6. [PubMed: 10529461]
245.
Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Thong CP. Comparative results in detection of HCV antibodies by using a rapid HCV test, ELISA and immunoblot. Southeast Asian J Trop Med Public Health. 1994;25(4):647–9. [PubMed: 7545315]
246.
Scalioni Lde P, Cruz HM, de Paula VS, Miguel JC, Marques VA, Villela-Nogueira CA et al. Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations. J Clin Virol. 2014;60(3):200–5. [PubMed: 24794796]
247.
Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis. 2011;204(6):825–31. [PubMed: 21849279]
248.
Yaari A, Tovbin D, Zlotnick M, Mostoslavsky M, Shemer-Avni Y, Hanuka N et al. Detection of HCV salivary antibodies by a simple and rapid test. J Virol Methods. 2006;133(1):1–5. [PubMed: 16360219]
249.
Daniel HD, Abraham P, Raghuraman S, Vivekanandan P, Subramaniam T, Sridharan G. Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies. J Clin Microbiol. 2005;43(4):1977–8. [PMC free article: PMC1081346] [PubMed: 15815036]
250.
Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101(11):2151–5. [PMC free article: PMC3222414] [PubMed: 21940910]
251.
Lee SR, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Friel T et al. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol. 2010;48(1):15–7. [PubMed: 20362493]
252.
Njouom R, Tejiokem MC, Zanga MC, Pouillot R, Ayouba A, Pasquier C et al. A cost-effective algorithm for the diagnosis of hepatitis C virus infection and prediction of HCV viremia in Cameroon. J Virol Methods. 2006;133(2):223–6. [PubMed: 16360220]
253.
O'Connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG et al. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings. Transfusion. 2013;53(3):505–17. [PubMed: 22823283]
254.
Yuen MF, Hui CK, Yuen JC, Young JL, Lai CL. The accuracy of SM-HCV rapid test for the detection of antibody to hepatitis C virus. Am J Gastroenterol. 2001;96(3):838–41. [PubMed: 11280561]
255.
Lee S, Kardos K, Yearwood G, Kurtz L, Roehler M, Feiss G. Results of a multi-center evaluation of a new rapid test for detection of HCV infection using whole blood, serum, plasma and oral fluid. J Hepatol. 2010;52(Suppl. 1):S271.
256.
Larrat S, Bourdon C, Baccard M, Garnaud C, Mathieu S, Quesada JL et al. Performance of an antigen-antibody combined assay for hepatitis C virus testing without venipuncture. J Clin Virol. 2012;55(3):220–5. [PubMed: 22901327]
257.
Smith BD, Teshale E, Jewett A, Weinbaum CM, Neaigus A, Hagan H et al. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis. 2011;53(8):780–6. [PubMed: 21921221]
258.
Mullis CE, Laeyendecker O, Reynolds SJ, Ocama P, Quinn J, Boaz I et al. High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis. 2013;57(12):1747–50. [PMC free article: PMC3840403] [PubMed: 24051866]
259.
Barreto AM, Takei K, E CS, Bellesa MA, Salles NA, Barreto CC et al. Cost-effective analysis of different algorithms for the diagnosis of hepatitis C virus infection. Braz J Med Biol Res. 2008;41(2):126–34. [PubMed: 18235967]
260.
Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 2001;26(4):340–4. [PubMed: 11317075]
261.
George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr. 2002;31(2):154–62. [PubMed: 12394793]
262.
Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000;38(2):575–7. [PMC free article: PMC86151] [PubMed: 10655348]
263.
Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23(1):89–93. [PMC free article: PMC2646374] [PubMed: 19050390]
264.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2. [PubMed: 19714720]
265.
Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139(2):483–90. [PubMed: 20451520]
266.
Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11(4):797–816. [PubMed: 17981229]
267.
Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125(1):80–8. [PubMed: 12851873]
268.
UNITAID. Hepatitis C diagnostic technology landscape. Geneva: World Health Organization; 2015 (http://unitaid​.org/images​/marketdynamics​/publications/UNITAID-HCV​_Diagnostic_Landscape-1st_edition​.pdf, accessed 5 February 2017).
269.
Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology. 1996;23(6):1330–3. [PubMed: 8675147]
270.
Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol. 2014;20(22):6701–6. [PMC free article: PMC4051911] [PubMed: 24944462]
271.
Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165(5):345–55. [PMC free article: PMC5345254] [PubMed: 27322622]
272.
Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol. 2000;38(11):4171–9. [PMC free article: PMC87559] [PubMed: 11060086]
273.
Yu ML, Chuang WL, Dai CY, Chen SC, Lin ZY, Hsieh MY et al. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test. J Clin Microbiol. 2000;38(8):2933–9. [PMC free article: PMC87152] [PubMed: 10921954]
274.
Sabato MF, Shiffman ML, Langley MR, Wilkinson DS, Ferreira-Gonzalez A. Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol. 2007;45(8):2529–36. [PMC free article: PMC1951251] [PubMed: 17567786]
275.
Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008;46(12):3880–91. [PMC free article: PMC2593291] [PubMed: 18799708]
276.
Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R et al. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol. 2012;55(1):17–22. [PubMed: 22698697]
277.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420. (http://www​.easl.eu/medias​/cpg/HEPC-revised-version​/English-report.pdf, accessed 5 February 2017). [PubMed: 24331294]
278.
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44. [PMC free article: PMC3229841] [PubMed: 21898493]
279.
Loggi E, Cursaro C, Scuteri A, Grandini E, Panno AM, Galli S et al. Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol. 2013;56(3):207–11. [PubMed: 23245628]
280.
Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T et al. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by pegylated interferon plus ribavirin combination therapy. J Dig Dis. 2009;10(1):21–5. [PubMed: 19236543]
281.
Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol. 2005;43(1):186–91. [PMC free article: PMC540104] [PubMed: 15634970]
282.
Feng B, Yang RF, Xie Q, Shang J, Kong FY, Zhang HY et al. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterol. 2014;14:47. [PMC free article: PMC3995626] [PubMed: 24625322]
283.
Moscato GA, Giannelli G, Grandi B, Pieri D, Marsi O, Guarducci I et al. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology. 2011;54(2):61–5. [PubMed: 20829601]
284.
Gu J, Yu T, Liang Z. Performances of HCV Ag or HCV RNA kits for screening of HCV-infected samples. Chinese Journal of Biologicals. 2014;27(9):1181–4.
285.
van Helden J, Weiskirchen R. Hepatitis C diagnostics: clinical evaluation of the HCV-core antigen determination. Z Gastroenterol. 2014;52(10):1164–70. [PubMed: 25313628]
286.
Schnuriger A, Dominguez S, Valantin MA, Tubiana R, Duvivier C, Ghosn J et al. Early detection of hepatitis C virus infection using a new combined antigen-antibody detection assay: potential use in HIV co-infected individuals. Pathol Biol (Paris). 2007;54(10):578–86. [PubMed: 17030457]
287.
Okazaki K, Nishiyama Y, Saitou T, Shibata N, Yamamoto C, Oosaga J et al. Fundamental evaluation of HCV core antigen method comparison with Cobas Amplicor HCV monitor v2.0 (high range method). Rinsho Byori. 2008;56(2):95–100. [PubMed: 18402050]
288.
Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015;60(12):1743–51. [PMC free article: PMC4834854] [PubMed: 25733369]
289.
Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus AD, Gruters RA. Current and future applications of dried blood spots in viral disease management. Antiviral Res. 2012;93(3):309–21. [PubMed: 22244848]
290.
Grüner N, Stambouli O, Ross RS. Dried blood spots – preparing and processing for use in immunoassays and in molecular techniques. J Vis Exp. 2015(97):52619. [PMC free article: PMC4397000] [PubMed: 25867233]
291.
McDade TW, Williams S, Snodgrass JJ. What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography. 2007;44(4):899–925. [PubMed: 18232218]
292.
Hirtz C, Lehmann S. Blood sampling using “dried blood spot”: a clinical biology revolution underway? Ann Biol Clin (Paris). 2015;73(1):25–37. [PubMed: 25582720]
293.
Ross RS, Stambouli O, Gruner N, Marcus U, Cai W, Zhang W et al. Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots – performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013;10:72. [PMC free article: PMC3599381] [PubMed: 23497102]
294.
Greenman J, Roberts T, Cohn J, Messac L. Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepat. 2015;22(4):353–61. [PMC free article: PMC4409077] [PubMed: 25367722]
295.
Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis MA. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review. Eur J Public Health. 2014;24(5):781–8. [PubMed: 24158318]
296.
Boa-Sorte N, Purificacao A, Amorim T, Assuncao L, Reis A, Galvao-Castro B. Dried blood spot testing for the antenatal screening of HTLV, HIV, syphilis, toxoplasmosis and hepatitis B and C: prevalence, accuracy and operational aspects. Braz J Infect Dis. 2014;18(6):618–24. [PMC free article: PMC9425210] [PubMed: 25022566]
297.
Forbi JC, Obagu JO, Gyar SD, Pam CR, Pennap GR, Agwale SM. Application of dried blood spot in the sero-diagnosis of hepatitis B infection (HBV) in an HBV hyper-endemic nation. Ann Afr Med. 2010;9(1):44–5. [PubMed: 20418650]
298.
Kania D, Bekale AM, Nagot N, Mondain AM, Ottomani L, Meda N et al. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa. Clin Microbiol Infect. 2013;19(12):E533–41. [PubMed: 23902574]
299.
Lee CE, Sri Ponnampalavanar S, Syed Omar SF, Mahadeva S, Ong LY, Kamarulzaman A. Evaluation of the dried blood spot (DBS) collection method as a tool for detection of HIV Ag/Ab, HBsAg, anti-HBs and anti-HCV in a Malaysian tertiary referral hospital. Ann Acad Med Singapore. 2011;40(10):448–53. [PubMed: 22206053]
300.
Mendy M, Kirk GD, van der Sande M, Jeng-Barry A, Lesi OA, Hainaut P et al. Hepatitis B surface antigenaemia and alpha-foetoprotein detection from dried blood spots: applications to field-based studies and to clinical care in hepatitis B virus endemic areas. J Viral Hepat. 2005;12(6):642–7. [PubMed: 16255766]
301.
Mohamed S, Raimondo A, Penaranda G, Camus C, Ouzan D, Ravet S et al. Dried blood spot sampling for hepatitis B virus serology and molecular testing. PLoS One. 2013;8(4):e61077. [PMC free article: PMC3628702] [PubMed: 23613788]
302.
Villa E, Cartolari R, Bellentani S, Rivasi P, Casolo G, Manenti F. Hepatitis B virus markers on dried blood spots. A new tool for epidemiological research. J Clin Pathol. 1981;34(7):809–12. [PMC free article: PMC493829] [PubMed: 7263909]
303.
Villar LM, de Oliveira JC, Cruz HM, Yoshida CF, Lampe E, Lewis-Ximenez LL. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. J Med Virol. 2011;83(9):1522–9. [PubMed: 21739441]
304.
Brandao CP, Marques BL, Marques VA, Villela-Nogueira CA, Do OK, de Paula MT et al. Simultaneous detection of hepatitis C virus antigen and antibodies in dried blood spots. J Clin Virol. 2013;57(2):98–102. [PubMed: 23518440]
305.
Tuaillon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology. 2010;51(3):752–8. [PubMed: 20043287]
306.
O'Brien J, Kruzel K, Wandell M, Vinogradov I, Sheagren J, Frank A. Detection of hepatitis C antibody with at-home collection kits using an innovative laboratory algorithm. Infect Disin Clin Pract. 2001;10(9):474–80.
307.
Croom HA, Richards KM, Best SJ, Francis BH, Johnson EI, Dax EM et al. Commercial enzyme immunoassay adapted for the detection of antibodies to hepatitis C virus in dried blood spots. J Clin Virol. 2006;36(1):68–71. [PubMed: 16426889]
308.
Marques BL, Brandao CU, Silva EF, Marques VA, Villela-Nogueira CA, Do OK et al. Dried blood spot samples: optimization of commercial EIAs for hepatitis C antibody detection and stability under different storage conditions. J Med Virol. 2012;84(10):1600–7. [PubMed: 22930508]
309.
Waterboer T, Dondog B, Michael KM, Michel A, Schmitt M, Vaccarella S et al. Dried blood spot samples for seroepidemiology of infections with human papillomaviruses, Helicobacter pylori, hepatitis C virus, and JC virus. Cancer Epidemiol Biomarkers Prev. 2012;21(2):287–93. [PubMed: 22147363]
310.
Nandagopal P, Iqbal HS, Saravanan S, Solomon SS, Mehta S, Selvakumar M et al. Evaluation of dried blood spot as an alternative specimen for the diagnosis of anti-HCV in resource-limited settings. Indian J Med Microbiol. 2014;32(2):208–10. [PubMed: 24713924]
311.
Dokubo EK, Evans J, Winkelman V, Cyrus S, Tobler LH, Asher A et al. Comparison of hepatitis C virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol. 2014;59(4):223–7. [PMC free article: PMC4026019] [PubMed: 24529844]
312.
Tejada-Strop A, Drobeniuc J, Mixson-Hayden T, Forbi JC, Le NT, Li L et al. Disparate detection outcomes for anti-HCV IgG and HCV RNA in dried blood spots. J Virol Methods. 2015;212:66–70. [PubMed: 25445800]
313.
Chevaliez S, Soulier A, Poiteau L, Pawlotsky JM. Dried blood spots (DBS), a promising tool for large-scale hepatitis C screening, diagnosis and treatment monitoring. International Liver Congress 2014. 49th Annual Meeting of the European Association for the Study of the Liver (EASL), 9–13 April 2014, London. J Hepatol. 2014;60 (1 Suppl):S325–S326. [Abstract P765]
314.
Parker SP, Cubitt WD, Ades AE. A method for the detection and confirmation of antibodies to hepatitis C virus in dried blood spots. J Virol Methods. 1997;68(2):199–205. [PubMed: 9389410]
315.
Lukacs Z, Dietrich A, Ganschow R, Kohlschutter A, Kruithof R. Simultaneous determination of HIV antibodies, hepatitis C antibodies, and hepatitis B antigens in dried blood spots – a feasibility study using a multi-analyte immunoassay. Clin Chem Lab Med. 2005;43(2):141–5. [PubMed: 15843206]
316.
McCarron B, Fox R, Wilson K, Cameron S, McMenamin J, McGregor G et al. Hepatitis C antibody detection in dried blood spots. J Viral Hepat. 1999;6(6):453–6. [PubMed: 10607263]
317.
Shepherd SJ, Kean J, Hutchinson SJ, Cameron SO, Goldberg DJ, Carman WF et al. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. J Clin Virol. 2013;57(1):29–35. [PubMed: 23369886]
318.
Alidjinou EK, Moukassa D, Sane F, Twagirimana Nyenyeli S, Akoko EC, Mountou MV et al. Detection of hepatitis B virus infection markers in dried plasma spots among patients in Congo-Brazzaville. Diagn Microbiol Infect Dis. 2014;78(3):229–31. [PubMed: 24342801]
319.
Alhusseini N, Abadeer M, El-Taher S. Hepatitis B virus DNA can be amplified directly from dried blood spot on filter paper. Am J Biochem Biotechnol. 2012;8(2):143–9.
320.
Durgadevi S, Dhodapkar R, Parija S. Serological and molecular diagnosis of hepatitis B virus. BMC Infect Dis. 2012;12(Suppl 1):P31.
321.
Gupta BP, Jayasuryan N, Jameel S. Direct detection of hepatitis B virus from dried blood spots by polymerase chain reaction amplification. J Clin Microbiol. 1992;30(8):1913–6. [PMC free article: PMC265415] [PubMed: 1500493]
322.
Halfon P, Raimondo A, Ouzan D, Bourlière M, Khiri H, Cohen-Bacrie S et al. Dried blood spot for hepatitis B virus serology and molecular testing. International Liver Congress 2012. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), 18–22 April 2012. Barcelona. J Hepatol. 2012;56 (Suppl 2):S62. [Abstract 142]
323.
Jardi R, Rodriguez-Frias F, Buti M, Schaper M, Valdes A, Martinez M et al. Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. Hepatology. 2004;40(1):133–9. [PubMed: 15239096]
324.
Lira R, Maldonado-Rodriguez A, Rojas-Montes O, Ruiz-Tachiquin M, Torres-Ibarra R, Cano-Dominguez C et al. Use of dried blood samples for monitoring hepatitis B virus infection. Virol J. 2009;6:153. [PMC free article: PMC2761391] [PubMed: 19788743]
325.
Vinikoor MJ, Zurcher S, Musukuma K, Kachuwaire O, Rauch A, Chi BH et al. Hepatitis B viral load in dried blood spots: a validation study in Zambia. J Clin Virol. 2015;72:20–4. [PMC free article: PMC4959444] [PubMed: 26356987]
326.
Abe K, Konomi N. Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. J Clin Microbiol. 1998;36(10):3070–2. [PMC free article: PMC105116] [PubMed: 9738072]
327.
Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO et al. Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol. 2012;54(2):106–9. [PubMed: 22418454]
328.
De Crignis E, Re MC, Cimatti L, Zecchi L, Gibellini D. HIV-1 and HCV detection in dried blood spots by SYBR Green multiplex real-time RT-PCR. J Virol Methods. 2010;165(1):51–6. [PubMed: 20045028]
329.
Soulier A, Poiteau L, Rosa I, Hezode C, Roudot-Thoraval F, Pawlotsky JM et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis. 2016;213(7):1087–95. [PubMed: 26333945]
330.
Santos C, Reis A, Dos Santos CV, Damas C, Silva MH, Viana MV et al. The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically. J Virol Methods. 2012;179(1):17–20. [PubMed: 21871496]
331.
Solmone M, Girardi E, Costa F, Pucillo L, Ippolito G, Capobianchi MR. Simple and reliable method for detection and genotyping of hepatitis C virus RNA in dried blood spots stored at room temperature. J Clin Microbiol. 2002;40(9):3512–4. [PMC free article: PMC130818] [PubMed: 12202607]
332.
Solmone M, Girardi E, Costa F, Ippolito G, Capobianchi MR. Simple and reliable method for HCV-RNA detection/genotyping in dried blood spots. J Hepatol. 2002;36(Suppl 1):131. [PMC free article: PMC130818] [PubMed: 12202607]
333.
Craine N, Whitaker R, Perrett S, Zou L, Hickman M, Lyons M. A stepped wedge cluster randomized control trial of dried blood spot testing to improve the uptake of hepatitis C antibody testing within UK prisons. Eur J Public Health. 2015;25(2):351–7. [PMC free article: PMC4376964] [PubMed: 25061233]
334.
Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15(4):250–4. [PubMed: 18086182]
335.
Hutchinson SJ, Dillon JF, Fox R, McDonald SA, Innes HA, Weir A et al. Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. Int J Drug Policy. 2015;26(11):1041–9. [PubMed: 26123893]
336.
Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. London: National Institute for Health and Clinical Excellence (NICE); 2012 (https://www​.nice.org​.uk/guidance/ph43/resources​/hepatitis-b-and-c-ways-to-promote-and-offer-testing-draft-guidance2, accessed 6 February 2017).
337.
McLeod A, Weir A, Aitken C, Gunson R, Templeton K, Molyneaux P et al. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. J Epidemiol Community Health. 2014;68(12):1182–8. [PubMed: 25170094]
338.
Place des tests rapides d'orientation diagnostique (TROD) dans la stratégie de dépistage de l'hépatite C. Saint-Denis La Plaine Cedex: Haute Autorité Sanitaire; 2014 (http://www​.has-sante​.fr/portail/upload/docs​/application/pdf/2014-05​/place_des_trod​_dans_la_strategie​_de_depistage_de_vhc-_rapport.pdf, accessed 6 February 2017).
339.
Bravo MJ, Vallejo F, Barrio G, Brugal MT, Molist G, Pulido J et al. HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. Int J Drug Policy. 2012;23(5):415–9. [PubMed: 22421554]
340.
Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy. 2012;23(5):346–52. [PubMed: 22940142]
341.
Allard NL, MacLachlan JH, Cowie BC. The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment. Aust N Z J Public Health. 2015;39(3):255–9. [PubMed: 25716519]
342.
Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd.The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554. [PMC free article: PMC4079454] [PubMed: 24988388]
343.
Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26(16):2059–67. [PubMed: 22781227]
344.
Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19 Suppl 3:S227–37. [PubMed: 16251823]
345.
Ahmed I, Habibi A, Iqbal J, Niaz Z, Naqvi A. Improving outcome in hepatitis C management: a need for dedicated multi-disciplinary service to improve compliance with treatment. J Gastroenterol Hepatol Res. 2013;2(8):737–9.
346.
Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–207. [PMC free article: PMC3820419] [PubMed: 21631316]
347.
Asthana A, Choong J, Lubel J. Education does not improve hepatitis B screening uptake in those receiving cytotoxic chemotherapy – time for alternative strategies. J Gastroenterol Hepatol. 2012;27:162.
348.
Bastani R, Glenn BA, Maxwell AE, Jo AM, Herrmann AK, Crespi CM et al. Cluster-randomized trial to increase hepatitis B testing among Koreans in Los Angeles. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1341–9. [PMC free article: PMC4560609] [PubMed: 26104909]
349.
Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC Jr, Monto A, Rossi SJ et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008;103(11):2757–65. [PubMed: 18684176]
350.
Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse. 2012;38(3):206–12. [PMC free article: PMC5573865] [PubMed: 22242700]
351.
Cacoub P, Ouzan D, Melin P, Lang JP, Rotily M, Fontanges T et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol. 2008;14(40):6195–203. [PMC free article: PMC2761581] [PubMed: 18985810]
352.
Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M, Canete N, Cirera I, Coll S et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol. 2013;59(5):926–33. [PubMed: 23811030]
353.
Chakrabarty G, Rice P, Forton D. Randomized controlled trial of home-based self-administered dried blood spot testing versus written advice for community screening of hepatitis B contacts. Hepatology. 2013;58:616A.
354.
Chen MS Jr, Fang DM, Stewart SL, Ly MY, Lee S, Dang JH et al. Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study. Cancer Epidemiol Biomarkers Prev. 2013;22(5):782–91. [PMC free article: PMC3650126] [PubMed: 23613027]
355.
Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11(6):362–71. [PMC free article: PMC4330991] [PubMed: 24535328]
356.
Cioe PA, Stein MD, Promrat K, Friedmann PD. A comparison of modified directly observed therapy to standard care for chronic hepatitis C. J Community Health. 2013;38(4):679–84. [PMC free article: PMC3706524] [PubMed: 23471655]
357.
Craine N, Parry J, O'Toole J, D'Arcy S, Lyons M. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service. J Viral Hepat. 2009;16(3):219–22. [PubMed: 19175879]
358.
Cullen W, Stanley J, Langton D, Kelly Y, Staines A, Bury G. Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. Br J Gen Pract. 2006;56(532):848–56. [PMC free article: PMC1927093] [PubMed: 17132352]
359.
Curcio F, Di Martino F, Capraro C, Angelucci F, Bulla F, Caprio N et al. Together ... to take care: multidisciplinary management of hepatitis C virus treatment in randomly selected drug users with chronic hepatitis. J Addict Med. 2010;4(4):223–32. [PubMed: 21769040]
360.
Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health. 2012;102(11):e115–21. [PMC free article: PMC3477946] [PubMed: 22994166]
361.
Evon DM, Simpson K, Kixmiller S, Galanko J, Dougherty K, Golin C et al. A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol. 2011;106(10):1777–86. [PMC free article: PMC3683982] [PubMed: 21769136]
362.
Hagedorn H, Dieperink E, Dingmann D, Durfee J, Ho SB, Isenhart C et al. Integrating hepatitis prevention services into a substance use disorder clinic. J Subst Abuse Treat. 2007;32(4):391–8. [PubMed: 17481462]
363.
Helsper CW, van Essen GA, Bonten MJ, de Wit NJ. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract. 2010;27(3):328–32. [PubMed: 20223833]
364.
Hirsch AA, Lawrence RH, Kern E, Falck-Ytter Y, Shumaker DT, Watts B. Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis. Jt Comm J Qual Patient Saf. 2014;40(8):351–7. [PubMed: 25208440]
365.
Ho SB, Brau N, Cheung R, Liu L, Sanchez C, Sklar M et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol. 2015;13(11):2005–14.e3 [PubMed: 25724704]
366.
Hsu L, Bowlus CL, Stewart SL, Nguyen TT, Dang J, Chan B et al. Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci. 2013;58(3):807–14. [PMC free article: PMC3578075] [PubMed: 23073671]
367.
Hussein M, Benner JS, Lee D, Sesti AM, Battleman DS, Brock-Wood C. Propensity score matching in the evaluation of drug therapy management programs: an illustrative analysis of a program for patients with hepatitis C virus. Qual Manag Health Care. 2010;19(1):25–33. [PubMed: 20042931]
368.
Juon HS, Lee S, Strong C, Rimal R, Kirk GD, Bowie J. Effect of a liver cancer education program on hepatitis B screening among Asian Americans in the Baltimore-Washington metropolitan area, 2009–2010. Prev Chronic Dis. 2014;11:130258. [PMC free article: PMC3921910] [PubMed: 24503341]
369.
Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M et al. Integrated psychiatric/ medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101(10):2254–62. [PubMed: 17032190]
370.
Koruk I, Koruk S, Çopur AC, Simsek Z. A intervention study to improve HBsAg testing and preventive practices for hepatitis B in an obstetrics hospital. TAF Prev Med Bull. 2011;10(3):287–92.
371.
Krauskopf K, Kil N, Sofianou A, Toribio W, Lyons J, Singer M et al. Evaluation of an electronic health record prompt for hepatitis c antibody screening of baby boomers in primary care – a cluster randomized control trial. J Gen Intern Med. 2014;29:S88–S9.
372.
Larrey D, Salse A, Ribard D, Boutet O, Hyrailles-Blanc V, Niang B et al. Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-alpha2a and ribavirin. Clin Gastroenterol Hepatol. 2011;9(9):781–5. [PubMed: 21683161]
373.
Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol. 2010;17(6):32–8. [PMC free article: PMC2993437] [PubMed: 21151407]
374.
Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis. 2012;44(6):497–503. [PubMed: 22342471]
375.
Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int. 2013;33(7):999–1007. [PMC free article: PMC3692599] [PubMed: 23509897]
376.
Ma GX, Gao W, Tan Y, Chae WG, Rhee J. A community-based participatory approach to a hepatitis B intervention for Korean Americans. Prog Community Health Partnersh. 2012;6(1):7–16. [PMC free article: PMC5573181] [PubMed: 22643783]
377.
Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103(10):e81–e8. [PMC free article: PMC3853128] [PubMed: 23947319]
378.
Matthews H, McLeod M, Oakes K, McCurdy G, Zuckerman M, Carey I et al. Perinatal hepatitis B in a high prevalence inner city population: direct electronic referral improves care. Gut. 2012;61:A79–A80.
379.
Merchant RC, Baird JR, Liu T, Taylor LE, Montague BT, Nirenberg TD. Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population. Acad Emerg Med. 2014;21(7):752–67. [PMC free article: PMC4135533] [PubMed: 25125271]
380.
Mostert MC, Richardus JH, de Man RA. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. J Hepatol. 2004;41(6):1026–30. [PubMed: 15582137]
381.
Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS et al. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol. 2010;44(9):e210–7. [PubMed: 20838237]
382.
Ramsey SE, Engler PA, Stein MD, Brown RA, Cioe P, Kahler CW et al. Effect of CBT on depressive symptoms in methadone maintenance patients undergoing treatment for hepatitis C. J Addict Res Ther. 2011;2(2):2–10. [PMC free article: PMC3130194] [PubMed: 21743837]
383.
Reimer J, Schmidt CS, Schulte B, Gansefort D, Golz J, Gerken G et al. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. Clin Infect Dis. 2013;57 (Suppl 2):S97–104. [PubMed: 23884073]
384.
Rifai MA, Moles JK, Lehman LP, Van der Linden BJ. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics. 2006;47(2):112–21. [PubMed: 16508022]
385.
Rosenberg SD, Goldberg RW, Dixon LB, Wolford GL, Slade EP, Himelhoch S et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr Serv. 2010;61(9):885–91. [PMC free article: PMC3632357] [PubMed: 20810586]
386.
Sahajian F, Excler G, Bailly F, Caillat-Vallet E, Trepo C, Sepetjan M et al. Hepatitis C screening practices among private practitioners: impact of an information campaign. Gastroenterol Clin Biol. 2004;28(8–9):714–9. [PubMed: 15646538]
387.
Tait JM, McIntyre PG, McLeod S, Nathwani D, Dillon JF. The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. J Viral Hepat. 2010;17(10):698–704. [PubMed: 20002561]
388.
Taylor VM, Bastani R, Burke N, Talbot J, Sos C, Liu Q et al. Evaluation of a hepatitis B lay health worker intervention for Cambodian Americans. J Community Health. 2013;38(3):546–53. [PMC free article: PMC3633619] [PubMed: 23299978]
389.
Taylor VM, Gregory Hislop T, Bajdik C, Teh C, Lam W, Acorda E et al. Hepatitis B ESL education for Asian immigrants. J Community Health. 2011;36(1):35–41. [PMC free article: PMC2952282] [PubMed: 20559696]
390.
Taylor VM, Hislop TG, Tu SP, Teh C, Acorda E, Yip MP et al. Evaluation of a hepatitis B lay health worker intervention for Chinese Americans and Canadians. J Community Health. 2009;34(3):165–72. [PMC free article: PMC2735565] [PubMed: 19127416]
391.
van der Veen YJ, van Empelen P, de Zwart O, Visser H, Mackenbach JP, Richardus JH. Cultural tailoring to promote hepatitis B screening in Turkish Dutch: a randomized control study. Health Promot Int. 2014;29(4):692–704. [PubMed: 23574695]
392.
Le Lan C, Guillygomarc'h A, Danielou H, Le Dreau G, Laine F, Vedeilhie C et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol. 2012;56(2):334–40. [PubMed: 21756854]
393.
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (OPTIMAL). Chronic Liver Disease Foundation; 2014. (https:​//clinicaltrials​.gov/ct2/show/NCT01405027, accessed 6 February 2017).
394.
Compliance of HCV genotype 1 infected patients receiving pegintron/rebetol and a patient assistance program (Study P04671). Merck Sharp & Dohme Corp.; 2007.
395.
Adherence in patients receiving pegintron pen/rebetol for hepatitis C in conjunction with a patient assistance program (Study P04281). Merck Sharp & Dohme Corp.; 2009.
396.
Adherence in patients receiving pegintron/rebetol for hepatitis C in conjunction with a psychotherapy support program (Study P04252). Merck Sharp & Dohme Corp.; 2009.
397.
Renou C LP, Pariente A. Impact of therapeutic education on the outcome of chronic hepatitis C treatment. Hepatology. 2009;50:729A.
398.
Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16(12):1409–22. [PubMed: 27615026]
399.
Mwai GW, Mburu G, Torpey K, Frost P, Ford N, Seeley J. Role and outcomes of community health workers in HIV care in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2013;16:18586. [PMC free article: PMC3772323] [PubMed: 24029015]
400.
Patel V, Weiss HA, Chowdhary N, Naik S, Pednekar S, Chatterjee S et al. Lay health worker led intervention for depressive and anxiety disorders in India: impact on clinical and disability outcomes over 12 months. Br J Psychiatry. 2011;199(6):459–66. [PMC free article: PMC3227809] [PubMed: 22130747]
401.
Joshi R, Alim M, Kengne AP, Jan S, Maulik PK, Peiris D et al. Task shifting for non-communicable disease management in low and middle income countries – a systematic review. PLoS One. 2014;9(8):e103754. [PMC free article: PMC4133198] [PubMed: 25121789]
402.
Kredo T, Adeniyi FB, Bateganya M, Pienaar ED. Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. Cochrane Database Syst Rev. 2014;(7):CD007331. [PubMed: 24980859]
403.
Glenton C, Colvin CJ, Carlsen B, Swartz A, Lewin S, Noyes J et al. Barriers and facilitators to the implementation of lay health worker programmes to improve access to maternal and child health: qualitative evidence synthesis. Cochrane Database Syst Rev. 2013;(10):CD010414. [PMC free article: PMC6396344] [PubMed: 24101553]
404.
Mandelblatt JS, Gold K, O'Malley AS, Taylor K, Cagney K, Hopkins JS et al. Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Prev Med. 1999;28(4):418–25. [PubMed: 10090871]
405.
Green BB, Wang CY, Anderson ML, Chubak J, Meenan RT, Vernon SW et al. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med. 2013;158(5 Pt 1):301–11. [PMC free article: PMC3953144] [PubMed: 23460053]
406.
Norman J, Walsh NM, Mugavin J, Stoove MA, Kelsall J, Austin K et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduct J. 2008;5:8. [PMC free article: PMC2291043] [PubMed: 18298862]
407.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L et al., for the STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Clin Chem. 2015;61(12):1446–52. [PubMed: 26510957]
408.
Guidance for post-market surveillance of in vitro diagnostics. Geneva: World Health Organization; 2015 (http://www​.who.int/diagnostics​_laboratory​/postmarket/150210_pms_ivds_guidance​.pdf?ua=1, accessed 02 July 2016, accessed 6 February 2017).
409.
Laboratory quality management system: handbook. World Health Organization; 2011 (http://www.who. int/ihr/publications/lqms/en/, accessed 6 February 2017).
410.
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Manual for use in primary care. Geneva: World Health Organization; 2011 (http://apps​.who.int/iris​/bitstream/10665​/44320/1/9789241599382_eng.pdf, accessed 23 January 2017).
411.
Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva: World Health Organization; 2007 (http://apps​.who.int/iris​/bitstream/10665​/43688/1/9789241595568_eng.pdf, accessed 6 February 2017).
412.
Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (http://www​.who.int/tb/tbscreening/en/, accessed 6 February 2017). [PubMed: 25996015]
413.
Corneli A, Jarrett NM, Sabue M, Duvall S, Bahati E, Behets F et al. Patient and provider perspectives on implementation models of HIV counseling and testing for patients with TB. Int J Tuberc Lung Dis. 2008;12 (3 Suppl 1):79–84. [PubMed: 18302828]
414.
Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization; 2003 (http://apps​.who.int/iris​/bitstream/10665​/42782/1/9241546263_eng.pdf?ua=1, 6 February 2017).
415.
Tucker JD, Bien CH, Peeling RW. Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis. 2013;26(1):73–9. [PMC free article: PMC3635142] [PubMed: 23242343]
416.
Dukers-Muijrers NH, Niekamp AM, Vergoossen MM, Hoebe CJ. Effectiveness of an opting-out strategy for HIV testing: evaluation of 4 years of standard HIV testing in a STI clinic. Sex Transm Infect. 2009;85(3):226–30. [PubMed: 19103641]
417.
Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57 (Suppl 2):S56–S61. [PMC free article: PMC6279207] [PubMed: 23884067]
418.
Islam MM, Topp L, Conigrave KM, White A, Reid SE, Grummett S et al. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. J Subst Abuse Treat. 2012;43(4):440–5. [PubMed: 22938915]
419.
Kresina TF, Lubran R, Clark HW, McCance-Katz EF. Advancing service integration in opioid treatment progams for the care and treatment of hepatitis C infection. Int J Clin Med. 2014;5(3):118–25.
420.
HIV indicator conditions: guidance for implementing HIV testing in adults in health care settings. Copenhagen: HIV in Europe; 2012 (http://hiveurope​.eu/Portals/0/Guidance​.pdf.pdf, accessed 6 February 2017).
421.
d'Almeida KW, Kierzek G, de Truchis P, Le Vu S, Pateron D, Renaud B et al. Modest public health impact of nontargeted human immunodeficiency virus screening in 29 emergency departments. Arch Intern Med. 2012;172(1):12–20. [PubMed: 22025095]
422.
Jones L, Bates G, McCoy E, Beynon C, McVeigh J, Bellis M. A systematic review of the effectiveness and cost-effectiveness of interventions aimed at raising awareness and engaging with groups who are at an increased risk of hepatitis B and C infection – final report. Liverpool: NICE; 2012 (https://www​.nice.org​.uk/guidance/ph43/evidence​/evidence-review-2-69062510, accessed 6 February 2017).
423.
Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther. 2009;29(1):38–45. [PubMed: 18945252]
424.
Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270–7. [PubMed: 20425880]
425.
Crawford S, Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clin Infect Dis. 2013;57 (Suppl 2):S75–9. [PubMed: 23884070]
426.
Evidence for action: effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug use. Geneva: World Health Organization; 2004 (http://www​.who.int/hiv​/pub/prev_care/en/evidenceforactionalcommunityfinal.pdf, accessed 6 February 2017).
427.
Hermez J, Petrak J, Karkouri M, Riedner G. A review of HIV testing and counseling policies and practices in the Eastern Mediterranean Region. AIDS. 2010;24 (Suppl 2):S25–S32. [PubMed: 20610945]
428.
Corbett EL, Dauya E, Matambo R, Cheung YB, Makamure B, Bassett MT et al. Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. PLoS Med. 2006;3(7):e238. [PMC free article: PMC1483908] [PubMed: 16796402]
429.
Collier AC, Van der Borght SF, Rinke de Wit T, Richards SC, Feeley FG. A successful workplace program for voluntary counseling and testing and treatment of HIV/AIDS at Heineken, Rwanda. International journal of occupational and environmental health. 2007;13(1):99–106. [PubMed: 17427354]
430.
Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, Pemba L et al. Evaluation of a workplace HIV treatment programme in South Africa. AIDS. 2007;21 (Suppl 3):S73–8. [PubMed: 17666964]
431.
Counselling and testing children for HIV in South Africa. Lancet. 2013;381(9865):424. [PubMed: 23399057]
432.
Ford N, Swan T, Beyer P, Hirnschall G, Easterbrook P, Wiktor S. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol. 2014;61(1 Suppl):S132–S8. [PubMed: 25443341]
433.
Xia J, Rutherford S, Ma Y, Wu L, Gao S, Chen T et al. Obstacles to the coordination of delivering integrated prenatal HIV, syphilis and hepatitis B testing services in Guangdong: using a needs assessment approach. BMC Health Serv Res. 2015;15:117. [PMC free article: PMC4378261] [PubMed: 25889645]
434.
Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106(2):148–55. [PubMed: 17339159]
435.
Community health workers: what do we know about them? The state of the evidence on programmes, activities, costs and impact on health outcomes of using community health workers. Geneva: World Health Organization; 2007 (http://www​.who.int/hrh​/documents/community_health_workers​.pdf, accessed 6 February 2017).
436.
Lewin SA, Dick J, Pond P, Zwarenstein M, Aja G, van Wyk B et al. Lay health workers in primary and community health care. Cochrane Database Syst Rev. 2005;(1):CD004015. [PubMed: 15674924]
437.
Laurant M, Reeves D, Hermens R, Braspenning J, Grol R, Sibbald B. Substitution of doctors by nurses in primary care. Cochrane Database Syst Rev. 2005;(2):CD001271. [PubMed: 15846614]
438.
Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8. [PMC free article: PMC2873343] [PubMed: 20356363]
439.
Task shifting: global recommendations and guidelines. Geneva: World Health Organization; 2007 (http://www​.who.int/healthsystems​/task_shifting/en/, accessed 6 February 2017).
440.
Optimizing health worker roles to improve access to key maternal and newborn health interventions through task shifting. Geneva: World Health Organization; 2012 (http://apps​.who.int/iris​/bitstream/10665​/77764/1/9789241504843_eng.pdf?ua=1, accessed 6 February 2017). [PubMed: 23844452]
441.
Walensky RP, Reichmann WM, Arbelaez C, Wright E, Katz JN, Seage GR 3rd et al. Counselor- versus provider-based HIV screening in the emergency department: results from the universal screening for HIV infection in the emergency room (USHER) randomized controlled trial. Ann Emerg Med. 2011;58(1 Suppl 1):S126–S132.e4. [PMC free article: PMC3268065] [PubMed: 21684391]
442.
Champenois K, Le Gall JM, Jacquemin C, Jean S, Martin C, Rios L et al. ANRS-COM'TEST: description of a community-based HIV testing intervention in non-medical settings for men who have sex with men. BMJ Open. 2012;2(2):e000693. [PMC free article: PMC3323802] [PubMed: 22466158]
443.
Lorente N, Preau M, Vernay-Vaisse C, Mora M, Blanche J, Otis J et al. Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (the ANRS-DRAG study). PLoS One. 2013;8(4):e61225. [PMC free article: PMC3628708] [PubMed: 23613817]
444.
Fylkesnes K, Sandoy IF, Jurgensen M, Chipimo PJ, Mwangala S, Michelo C. Strong effects of home-based voluntary HIV counselling and testing on acceptance and equity: a cluster randomised trial in Zambia. Soc Sci Med. 2013;86:9–16. [PubMed: 23608089]
445.
Molesworth AM, Ndhlovu R, Banda E, Saul J, Ngwira B, Glynn JR et al. High accuracy of home-based community rapid HIV testing in rural Malawi. J Acquir Immune Defic Syndr. 2010;55(5):625–30. [PMC free article: PMC3248920] [PubMed: 21934554]
446.
Bemelmans M, van den Akker T, Ford N, Philips M, Zachariah R, Harries A et al. Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health. 2010;15(12):1413–20. [PubMed: 20958897]
447.
Jackson D, Naik R, Tabana H, Pillay M, Madurai S, Zembe W et al. Quality of home-based rapid HIV testing by community lay counsellors in a rural district of South Africa. J Int AIDS Soc. 2013;16:18744. [PMC free article: PMC3830054] [PubMed: 24241957]
448.
Iwu EN, Holzemer WL. Task shifting of HIV management from doctors to nurses in Africa: clinical outcomes and evidence on nurse self-efficacy and job satisfaction. AIDS Care. 2014;26(1):42–52. [PubMed: 23701374]
449.
Leon N, Naidoo P, Mathews C, Lewin S, Lombard C. The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial. Implement Sci. 2010;5:8. [PMC free article: PMC2825497] [PubMed: 20205841]
450.
Kanal K, Chou TL, Sovann L, Morikawa Y, Mukoyama Y, Kakimoto K. Evaluation of the proficiency of trained non-laboratory health staffs and laboratory technicians using a rapid and simple HIV antibody test. AIDS Res Ther. 2005;2(1):5. [PMC free article: PMC1156864] [PubMed: 15907202]
451.
Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis. 2013;56(8):1078–84. [PubMed: 23362288]
452.
Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol. 2008;22(1):27–32. [PMC free article: PMC2659116] [PubMed: 18209777]
453.
UNITAID. Hepatitis C medicines and diagnostics in the context of HIV/HCV co-infection: a scoping report. Geneva: World Health Organization; 2013 (http://www​.unitaid.eu​/images/marketdynamics​/publications/Hepatitis-C​_October-2013.pdf, accessed 23 January 2017).
454.
Pant Pai N, Sharma J, Shivkumar S, Pillay S, Vadnais C, Joseph L et al. Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a systematic review. PLoS Med. 2013;10(4):e1001414. [PMC free article: PMC3614510] [PubMed: 23565066]
455.
Krause J, Subklew-Sehume F, Kenyon C, Colebunders R. Acceptability of HIV self-testing: a systematic literature review. BMC Public Health. 2013;13:735. [PMC free article: PMC3750621] [PubMed: 23924387]
456.
Figueroa C, Johnson C, Verster A, Baggaley R. Attitudes and acceptability on HIV aelf-testing among key populations: a literature review. AIDS Behav. 2015;19(11):1949–65. [PMC free article: PMC4598350] [PubMed: 26054390]
457.
Choko AT, MacPherson P, Webb EL, Willey BA, Feasy H, Sambakunsi R et al. Uptake, accuracy, safety, and linkage into care over two years of promoting annual self-testing for HIV in Blantyre, Malawi: a community-based prospective study. PLoS Med. 2015;12(9):e1001873. [PMC free article: PMC4562710] [PubMed: 26348035]
458.
HIV/AIDS prevention, care, treatment and support in prison settings: a framework for an effective national response. Vienna: United Nations Office on Drugs and Crime; 2006 (http://www​.who.int/hiv​/pub/idu/framework_prisons.pdf?ua=1, accessed 6 February 2017).
459.
Policy brief. HIV prevention, treatment and care in prisons and other closed settings: a comprehensive package of interventions. Vienna: United Nations Office on Drugs and Crime; 2013 (https://www​.unodc.org​/documents/hiv-aids​/HIV_comprehensive_package​_prison_2013_eBook.pdf, accessed 6 February 2017).
460.
Grebely J, Bruggmann P, Treloar C, Byrne J, Rhodes T, Dore GJ et al. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10):893–8. [PubMed: 26254497]
461.
Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs: consolidated guidelines. Geneva: World Health Organization; 2016 (http://apps​.who.int/iris​/bitstream/10665​/204484/1/9789241510226_eng.pdf?ua=1, accessed 6 February 2017).
462.
Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054–8. [PubMed: 10498659]
463.
Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34(6):1193–9. [PubMed: 11732009]
464.
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562–9. [PubMed: 11462196]
465.
Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369–79. [PMC free article: PMC4254786] [PubMed: 24723077]
466.
Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22. [PubMed: 23467291]
467.
Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS. 2012;7(4):345–53. [PubMed: 22678489]
468.
Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people who use and inject illicit drugs. Bull World Health Organ. 2013;91(2):154–6. [PMC free article: PMC3605021] [PubMed: 23554532]
469.
Padmapriyadarsini C, Chandrabose J, Victor L, Hanna LE, Arunkumar N, Swaminathan S. Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J Postgrad Med. 2006;52(2):92–6. [PubMed: 16679670]
470.
Liu R, Li Y, Wangen KR, Maitland E, Nicholas S, Wang J. Analysis of hepatitis B vaccination behavior and vaccination willingness among migrant workers from rural China based on protection motivation theory. Hum Vaccin Immunother. 2016;12(5):1155–63. [PMC free article: PMC4963072] [PubMed: 27078191]
471.
Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. Geneva: World Health Organization; 2012 (http://apps​.who.int/iris​/bitstream/10665​/44646/1/9789241501972_eng.pdf?ua=1, accessed 6 February 2017). [PubMed: 23700649]
472.
Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol. 2014;11(7):402–9. [PMC free article: PMC6658169] [PubMed: 24686270]
473.
Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19(48):9377–82. [PMC free article: PMC3882411] [PubMed: 24409065]
474.
HIV and adolescents: guidance for HIV testing and counseling and care for adolescents living with HIV. Recommendations for a public health approach and consideration for policy-makers and managers. Geneva: World Health Organization; 2013 (http://apps​.who.int/iris​/bitstream/10665​/94334/1/9789241506168_eng.pdf?ua=1, accessed 6 February 2017). [PubMed: 25032477]